(MENAFN- GlobeNewsWire - Nasdaq) MARLBOROUGH, Mass., BERLIN and YOKNEAM ILIT, Israel, Feb. 17, 2020 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) ('ReWalk' or the 'Company') today announced that the Company will release its fourth quarter and year-end 2019 financial results on Thursday, February 20, 2020, before the U.S. financial markets open.
Larry Jasinski, Chief Executive Officer, and Ori Gon, Chief Financial Officer, will host a conference call to discuss the results as follows:
| Time | 8:30 A.M EST |
| Toll free (U.S.) | (844) 423-9889 |
| International (U.S) | (716) 247-5804 |
| Germany | 08 00 18 15 287 |
| Israel | 18 09 31 53 62 |
| Access Code | 7697891 |
| Webcast (live and replay) | https://edge.media-server.com/mmc/p/nmw53r5v
under the 'Investors' section'. |
The archived webcast will be available via the following URL https://edge.media-server.com/mmc/p/nmw53r5v or through the 'Investors' section' on www.rewalk.com .
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk's mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com .
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the Unites States.
Investor Contact:
Ori Gon
Chief Financial Officer
ReWalk Robotics Ltd.
T: +972-4-9590123
E:
MENAFN1702202000703653ID1099716516
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.